Microspheres as a Carrier System for Therapeutic Embolization Procedures : Achievements and Advances
The targeted delivery of anti-cancer drugs and isotopes is one of the most pursued goals in anti-cancer therapy. One of the prime examples of such an application is the intra-arterial injection of microspheres containing cytostatic drugs or radioisotopes during hepatic embolization procedures. Therapy based on the application of microspheres revolves around vascular occlusion, complemented with local therapy in the form of trans-arterial chemoembolization (TACE) or radioembolization (TARE). The broadest implementation of these embolization strategies currently lies within the treatment of untreatable hepatocellular cancer (HCC) and metastatic colorectal cancer. This review aims to describe the state-of-the-art TACE and TARE technologies investigated in the clinical setting for HCC and addresses current trials and new developments. In addition, chemical properties and advancements in microsphere carrier systems are evaluated, and possible improvements in embolization therapy based on the modification of and functionalization with therapeutical loads are explored.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Journal of clinical medicine - 12(2023), 3 vom: 24. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Welling, Mick M [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Embolization |
|---|
| Anmerkungen: |
Date Revised 14.02.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/jcm12030918 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352792809 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352792809 | ||
| 003 | DE-627 | ||
| 005 | 20231226054529.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/jcm12030918 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1175.xml |
| 035 | |a (DE-627)NLM352792809 | ||
| 035 | |a (NLM)36769566 | ||
| 035 | |a (PII)918 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Welling, Mick M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Microspheres as a Carrier System for Therapeutic Embolization Procedures |b Achievements and Advances |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 14.02.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a The targeted delivery of anti-cancer drugs and isotopes is one of the most pursued goals in anti-cancer therapy. One of the prime examples of such an application is the intra-arterial injection of microspheres containing cytostatic drugs or radioisotopes during hepatic embolization procedures. Therapy based on the application of microspheres revolves around vascular occlusion, complemented with local therapy in the form of trans-arterial chemoembolization (TACE) or radioembolization (TARE). The broadest implementation of these embolization strategies currently lies within the treatment of untreatable hepatocellular cancer (HCC) and metastatic colorectal cancer. This review aims to describe the state-of-the-art TACE and TARE technologies investigated in the clinical setting for HCC and addresses current trials and new developments. In addition, chemical properties and advancements in microsphere carrier systems are evaluated, and possible improvements in embolization therapy based on the modification of and functionalization with therapeutical loads are explored | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a TACE | |
| 650 | 4 | |a TAE | |
| 650 | 4 | |a TARE | |
| 650 | 4 | |a embolization | |
| 650 | 4 | |a hepatocellular carcinoma | |
| 650 | 4 | |a microspheres | |
| 650 | 4 | |a therapy | |
| 700 | 1 | |a Duszenko, Nikolas |e verfasserin |4 aut | |
| 700 | 1 | |a van Meerbeek, Maarten P |e verfasserin |4 aut | |
| 700 | 1 | |a Molenaar, Tom J M |e verfasserin |4 aut | |
| 700 | 1 | |a Buckle, Tessa |e verfasserin |4 aut | |
| 700 | 1 | |a van Leeuwen, Fijs W B |e verfasserin |4 aut | |
| 700 | 1 | |a Rietbergen, Daphne D D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical medicine |d 2012 |g 12(2023), 3 vom: 24. Jan. |w (DE-627)NLM230666310 |x 2077-0383 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2023 |g number:3 |g day:24 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/jcm12030918 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2023 |e 3 |b 24 |c 01 | ||